Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schweiger

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Environmental Science & Technology|July 12, 2017
Reduction and Simultaneous Removal of <sup>99</sup>Tc and Cr by Fe(OH)<sub>2</sub>(s) Mineral TransformationSarah A Saslow, Wooyong Um, Carolyn I Pearce, et al.
The American Journal of Cardiology|October 7, 1997
Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial InfarctionC P Cannon, P J Sharis, M J Schweiger, et al.
European Heart Journal|July 22, 1999
Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction. A TIMI-IIIB database studyP H Stone, B Thompson, B L Zaret, et al.
Nature Communications|February 8, 2022
Mesenchymal-epithelial crosstalk shapes intestinal regionalisation via Wnt and Shh signallingMartti Maimets, Marianne Terndrup Pedersen, Jordi Guiu, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
Critical Pathways in Cardiology|March 15, 2008
Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 RegistryChristopher P Cannon, Maria Cecilia Bahit, J Mark Haugland, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activityJeffrey R Roppe, Bowei Wang, Dehua Huang, et al.
European Heart Journal. Acute Cardiovascular Care|November 14, 2013
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACSConnie N Hess, Phillip J Schulte, L Kristin Newby, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 7, 2009
Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programmeJohn M Lasala, David A Cox, Stephen J Lewis, et al.
Bioorganic & Medicinal Chemistry Letters|August 24, 2005
Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonistsPeter C Chua, Johnny Y Nagasawa, Leo S Bleicher, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Environmental Science & Technology|July 12, 2017
Reduction and Simultaneous Removal of <sup>99</sup>Tc and Cr by Fe(OH)<sub>2</sub>(s) Mineral TransformationSarah A Saslow, Wooyong Um, Carolyn I Pearce, et al.
The American Journal of Cardiology|October 7, 1997
Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial InfarctionC P Cannon, P J Sharis, M J Schweiger, et al.
European Heart Journal|July 22, 1999
Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction. A TIMI-IIIB database studyP H Stone, B Thompson, B L Zaret, et al.
Nature Communications|February 8, 2022
Mesenchymal-epithelial crosstalk shapes intestinal regionalisation via Wnt and Shh signallingMartti Maimets, Marianne Terndrup Pedersen, Jordi Guiu, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
Critical Pathways in Cardiology|March 15, 2008
Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 RegistryChristopher P Cannon, Maria Cecilia Bahit, J Mark Haugland, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activityJeffrey R Roppe, Bowei Wang, Dehua Huang, et al.
European Heart Journal. Acute Cardiovascular Care|November 14, 2013
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACSConnie N Hess, Phillip J Schulte, L Kristin Newby, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 7, 2009
Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programmeJohn M Lasala, David A Cox, Stephen J Lewis, et al.
Bioorganic & Medicinal Chemistry Letters|August 24, 2005
Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonistsPeter C Chua, Johnny Y Nagasawa, Leo S Bleicher, et al.
Pageof 8